Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: A randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 312, Issue 17, 2014, Pages 1744-1753

  Hodi, F Stephen ^a   Lee, Sandra ^a,b   McDermott, David F ^b,c   Rao, Uma N ^d   Butterfield, Lisa H ^d   Tarhini, Ahmad A ^d   Leming, Philip ^e,f   Puzanov, Igor ^g   Shin, Donghoon ^a,b   Kirkwood, John M ^d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e CHRIST HOSPITAL   (United States)

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INTERFERON; IPILIMUMAB; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; SARGRAMOSTIM;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER PATIENT; CANCER STAGING; CENTRAL NERVOUS SYSTEM METASTASIS; COLITIS; COLON DISEASE; COLON PERFORATION; COLONIC FAILURE; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE DISEASE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEART ARREST; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; HYPONATREMIA; IMMUNOPATHOLOGY; INFECTION; INJURY; LIVER FAILURE; LUNG TOXICITY; MACULOPAPULAR RASH; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METASTATIC MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SKIN TOXICITY; SURVIVAL TIME; SYSTEMIC THERAPY; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE; VASCULAR DISEASE; VERY ELDERLY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MELANOMA; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; SKIN NEOPLASMS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; RECOMBINANT PROTEINS; SKIN NEOPLASMS;

EID: 84908664534     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.13943     Document Type: Article

References (40)

1. Inaba K, Inaba M, Romani N., et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992; 176(6):1693-1702.
2. Fischer HG, Frosch S, Reske K., Reske-Kunz AB. Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J Immunol. 1988; 141(11):3882-3888.
3. Weisbart RH, Golde DW, Clark S.C., Wong GG, Gasson JC. Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator. Nature. 1985; 314(6009):361-363.
4. Small EJ, Reese DM, Um B, Whisenant S., Dixon SC, Figg WD. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 1999; 5(7):1738-1744.
5. Everly JJ, Lonial S. Immunomodulatory effects of human recombinant granulocyte-macrophage colony-stimulating factor (rhuGM-CSF): evidence of antitumour activity. Expert Opin Biol Ther. 2005; 5 (3):293-311.
6. + T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res. 2009; 15(22):7036-7044.
7. Hodi FS, O'Day SJ, McDermott DF, et al Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8): 711-723.
8. Robert C, Thomas L, Bondarenko I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364(26):2517-2526.
9. van Elsas A., Hurwitz AA, Allison JP Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999; 190(3):355-366.
10. Hodi FS, Mihm MC, Soiffer R.J., et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003; 100(8):4712-4717.
11. Hodi FS, Butler M, Oble D.A., et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA. 2008; 105(8):3005-3010.
12. van den Eertwegh AJ, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012; 13(5):509-517.
13. Fong L, Kwek SS, O'Brien S, et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 2009; 69 (2):609-615.
14. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15(23):7412-7420.
15. O'Brien P.C., Fleming TR A multiple testing procedure for clinical trials. Biometrics. 1979; 35(3): 549-556.
16. Jennison C, Turnbull BW Group sequential analysis incorporating covariate information. J Am Stat Assoc. 1997; 92(440):1330-1341. doi:10.1080/01621459.1997.10473654
17. Fu T, He Q, Sharma P. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res. 2011; 71(16):5445-5454.
18. + CD4 T-cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Re. 2014; 2(5):501. Medline:24777852
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53 (282):457-481. doi:10.1080/01621459.1958.10501452
20. Cox DR. Regression models and life tables. J R Stat Soc Series B Stat Methodol. 1972; 34 (2):187-220. http://www.jstor.org/stable/2985181. Accessed October, 14, 2014.
21. Agresti A. Categorical Data Analysis. New York, NY: Wiley; 1990.
22. Korn EL, Liu PY, Lee S.J., et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008; 26(4):527-534.
23. Kantoff PW, Higano CS, Shore N.D., et al; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363(5):411-422.
24. Quezada SA, Peggs KS, Curran M.A., Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest. 2006; 116(7):1935-1945.
25. Jinushi M, Nakazaki Y, Dougan M., Carrasco DR, Mihm M, Dranoff G. MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. J Clin Invest. 2007; 117(7):1902-1913.
26. Filipazzi P, Valenti R, Huber V., et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007; 25(18):2546-2553.
27. Parmiani G, Castelli C, Pilla L., Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol. 2007; 18(2): 226-232.
28. Sotomayor EM, Fu YX, Lopez-Cepero M, et al. Role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. J Immunol. 1991; 147(8):2816-2823.
29. Selby MJ, Engelhardt JJ, Quigley M, et al Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2013; 1(1):32-42.
30. Hercus TR, Thomas D, Guthridge M.A., et al. The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood. 2009; 114(7):1289-1298.
31. Han X, Uchida K, Jurickova I., et al Granulocyte-macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn's disease. Gastroenterology. 2009; 136(4): 1261-1271.
32. Goldstein JI, Kominsky DJ, Jacobson N, et al Defective leukocyte GM-CSF receptor (CD116) expression and function in inflammatory bowel disease. Gastroenterology. 2011; 141(1):208-216.
33. Dranoff G. Granulocyte-macrophage colony stimulating factor and inflammatory bowel disease: establishing a connection. Gastroenterology. 2011; 141(1):28-31.
34. Egea L, Hirata Y, Kagnoff MFGM-CSF. GM-CSF: a role in immune and inflammatory reactions in the intestine. Expert Rev Gastroenterol Hepatol. 2010; 4 (6):723-731.
35. Xu Y, Hunt NH, Bao S. The role of granulocyte macrophage-colony-stimulating factor in acute intestinal inflammation. Cell Res. 2008; 18(12):1220-1229.
36. + regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med. 2007; 204(8):1757-1764.
37. Fukuzawa H, Sawada M, Kayahara T., et al. Identification of GM-CSF in Paneth cells using single-cell RT-PCR. Biochem Biophys Res Commun. 2003; 312(4):897-902.
38. Dranoff G, Crawford AD, Sadelain M, et al Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science. 1994; 264(5159):713-716.
39. + regulatory T cells and promote airway tolerance. J Exp Med. 2013; 210(4):775-788.
40. Topalian SL, Hodi FS, Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26): 2443-2454.